Nomic Bio
PrivateLast Round
Series B
Sep 17, 2024
Total Funding Raised
$59.17M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Nomic Bio is a biotechnology company that provides a high-throughput proteomic platform to facilitate protein measurement and custom panel development for drug discovery and biomarker identification.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Biotech Equipment, Precision Medicine
Business Model
B2B
Customer Profile
Usage-Based SaaS, Services & Consulting
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nomic Bio Comparables
Compare Nomic Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Alamar Biosciences | 78% | |
| Nautilus Biotechnology | 78% | |
| Thermo Fisher Scientific Inc. | 78% |
Nomic Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Sep 17, 2024 | ||||
| Series A | Dec 8, 2021 | ||||
| Accelerator | Mar 16, 2020 | ||||
| Grant | Apr 9, 2019 |
Key People
Founding team and executive leadership
Nomic Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Amplitude Ventures | Series B |
| Lux Capital | Series B, Series A |
| First Star Ventures | Accelerator |
| BoxOne Ventures | Accelerator |
| Real Ventures | Accelerator, Series B, Series A |
| 2048 Ventures | Series A, Accelerator |
| Y Combinator | Accelerator, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 249% MoM, reaching 31.8K.
- Jul 24, 2026
Monthly visitors increased 58% MoM, reaching 9.1K.
Recent news
Latest coverage and updates
- is_developingNov 4, 2026
Nomic plans to develop a multiomic reference database characterizing the human immune response, with the plans announced in New York in Oct '26.
- launchesNov 1, 2026
Nomic launches the 100-million-cell immune dataset to advance AI drug discovery on Nov 1st '26.
- is_developingOct 29, 2026
Nomic partners with Parse Biosciences to develop Cascade, a planned multimodal, time-resolved dataset combining 100 million single-cell RNA profiles with more than 11,000 quantitative protein profiles to support AI models of immune biology, announced in Canada on Oct 29th '26.
Nomic Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Nomic Bio's valuation, stock price, and market status.
Is Nomic Bio a public or private company?
Nomic Bio is a private company.
What is the current stock price of Nomic Bio?
Nomic Bio is a private company, so its shares have no public market price. Caplight tracks Nomic Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nomic Bio worth (valuation)?
Valuation information for Nomic Bio is not publicly available.
Can I buy Nomic Bio stock?
Nomic Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nomic Bio's last funding round?
Nomic Bio's most recent funding round was Series B on September 17, 2024.
Who are the main investors in Nomic Bio?
Key investors in Nomic Bio include Lux Capital, 2048 Ventures, SR One, AVANT BIO.
Will Nomic Bio IPO soon?
No public IPO plans have been announced for Nomic Bio.
How can I track Nomic Bio secondary market activity?
Caplight tracks bids, offers, and trades in Nomic Bio's shares on secondary markets.